Evidence-based guideline update: Treatment of Essential Tremor
Neurol 77:1752-1755, Zesiewicz, T.A.,et al, 2011
Clinical Update:Diagnosis and Treatment of Essential Tremor
Lancet 369:1152-1154, Benito-Leon,J&Louis,E.D., 2007
Syncope and Falls Due to Timolol Eye Drops
BMJ 332:960-961, Mller,M.E.,et al, 2006
Verapamil Induced Gingival Enlargement in Cluster Headache
JNNP 76:124-127, Matharu,M.S.,et al, 2005
Tetraparesis Associated with Colchicine is Probably Due to Inhibition by Verapamil of the P-glycoprotein Efflux Pump in the Blood-Brain Barrier
BMJ 331:513, Troger,U.,et al, 2005
Multifocal Myoclonus Due to Verapamil Overdose
Neurol 58:984-985, Vadlamudi,L.&Wijdicks,E.F.M., 2002
Asystole Induced by Edrophonium Following Beta Blockade
Neurol 57:739, Okun,M.S.,et al, 2001
Treatment of Postural Hypotension
JNNP 65:285-289, Mathias,C.J.&Kimber,J.R., 1998
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Management of the Behavioral Manifestations of Dementia
Arch Int Med 155:250-260, Yeager,B.F.,et al, 1995
Recurrent Migraine and Intravenous Immune Globulin Therapy
NEJM 329:583-584, Constantinescu,C.S.,et al, 1993
Parkinsonism Unmasked by Verapamil
Clinical Neuropharmacol 16:263-265, Garcia-Albea,E.,et al, 1993
Metoprolol-Induced Polymyalgia-Like Syndrome
Ann Int Med 114:96-97, Snyder,S., 1991
Exacerbation of Vasodepressor Syncope by Beta-Adrenergic Blockade
NEJM 324:1219-1220, Chan,W.L.,et al, 1991
Interactions Between Calcium Channel Blockers and the Anticonvulsants Carbamazepine and Phenytoin
Neurol 41:740-742, Bahls,F.H.,et al, 1991
Syncope and Presyncope Associated with Probable Adverse Drug Reactions
Arch Int Med 150:2309-2312, Hanlon,J.T.,et al, 1990
Cognitive Impairment Associated with Beta-Blockade in the Elderly
Postgrad Med J 66:1050-1052, Rogers,T.K.&Bowman,C.E., 1990
Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990
Neuropsychological Side Effects of B-Blockers
Arch Int Med 149:514-525, Dimsdale,J.E.,et al, 1989
Acute and Chronic Effects of Propranolol and Primidone in Essential Tremor
Neurol 39:1587-1588, Koller,W.C.&Vetere-Overfield,B., 1989
Beta-Blockers and Glucose Control
Drug Intell Clin Pharm 19:246-251, Mills,G.A.&Horn,J.R., 1985
Drug-Induced Seizures:A 10-Year Experience
Neurol 34:1582-1586, Messing,R.O.,et al, 1984
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency
JAMA 310:2435-2442, Lam, J.R.,et al, 2013
Multimodal Imaging of Reversible Cerebral Vasoconstriction Syndrome: A Series of 6 Cases
AJNR 33:1403-1410, Marder, C.P.,et al, 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Pregnancy and Fetal Outcomes After Interferon-b Exposure in Multiple Sclerosis
Neurol 75:1794-1802, Amato,M.P.,et al, 2010
Assessment of Potential Drug Interactions in Patients with Epilepsy: Impact of Age and Sex
Neurol 72:419-425, Gidal,B.E.,et al, 2009
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008
Interferon �-Associated Retinopathy in Patients Treated for Multiple Sclerosis
Neurol 70:1153-1155, Folden,D.V.,et al, 2008
Combining Beta Interferon and Atorvastatin May Increase Disease Activity in Multiple Sclerosis
Neurol 71:1390-1395,1386, Birnbaum,G.,et al, 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Safety and Tolerability of Interferon Beta-1b in Pediatric Multiple Sclerosis
Neurol 66:472-476, Banwell,B.,et al, 2006
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005